SLEEP QUALITY AND HUMAN AMLYOID-BETA KINETICS

项目总结： Brendan Lucey博士，医学博士，是一位积极进取的内科科学家，对睡眠、衰老和 神经退行性疾病，如阿尔茨海默病。他是神经学助理教授(终身教职 Track)，并正在寻求这一行政补充资金用于研究费用 探讨脑脊液tau、磷酸化tau(p-tau)和α突触核蛋白的新变化 食欲素受体拮抗剂对睡眠觉醒活性和药理诱导睡眠的影响 来自Suvorexant的。露西博士的长期目标是开发一个令人兴奋的研究计划，研究 睡眠、衰老和阿尔茨海默病之间的相互关系。了解这些关系可能会 推动开发预防或延缓阿尔茨海默病的新疗法。这项管理工作 补充请求建立在最近发表的研究和我们未发表的初步数据显示睡眠 丢失会增加脑脊液中tau和α-突触核蛋白的浓度，并影响 磷酸化tau(p-tau)。此外，本补充资料将利用收集的新颖样本作为 家长助学金。

Project Summary: Dr. Brendan Lucey, MD is a highly-motivated physician-scientist with a strong interest in sleep, aging, and neurodegenerative disorders such as Alzheimer’s disease. He is an Assistant Professor of Neurology (tenure track) at Washington University and is seeking support from this administrative supplement for research costs to explore novel changes in cerebrospinal fluid (CSF) tau, phosphorylated tau (p-tau), and α-synuclein concentrations with sleep-wake activity and pharmacologic sleep induction via orexin receptor antagonism from suvorexant. Dr. Lucey’s long-term goal is to develop an exciting research program investigating the interrelationships between sleep, aging, and Alzheimer’s disease. Understanding these relationships could drive the development of new treatments to prevent or delay Alzheimer’s disease. This administrative supplement request builds on recently published work and our unpublished preliminary data showing that sleep loss increases concentrations of tau and α-synuclein in cerebrospinal fluid (CSF) and affects the forms of phosphorylated tau (p-tau). Further, this supplement will leverage novel samples collected as part of the parent grant.